Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women.
Reads0
Chats0
TLDR
It is proposed that intravenous iron lowers cF GF23 in humans by reducing fgf23 transcription as it does in mice, whereas carbohydrate moieties in certain iron preparations may simultaneously inhibit FGF23 degradation in osteocytes leading to transient increases in iFGF23 and reduced serum phosphate.Abstract:
Fibroblast growth factor 23 (FGF23) is an osteocyte-derived hormone that regulates phosphate and vitamin D homeostasis. Through unknown mechanisms, certain intravenous iron preparations induce acute, reversible increases in circulating FGF23 levels that lower serum phosphate in association with inappropriately low levels of calcitriol, similar to genetic diseases of primary FGF23 excess. In contrast, studies in wild-type mice suggest that iron deficiency stimulates fgf23 transcription but does not result in hypophosphatemia because FGF23 is cleaved within osteocytes by an unknown catabolic system. We tested the association of iron deficiency anemia with C-terminal FGF23 (cFGF23) and intact FGF23 (iFGF23) levels in 55 women with a history of heavy uterine bleeding, and assessed the longitudinal biochemical response over 35 days to equivalent doses of randomly-assigned, intravenous elemental iron in the form of ferric carboxymaltose (FCM) or iron dextran. Iron deficiency was associated with markedly elevated cFGF23 (807.8 ± 123.9 relative units [RU]/mL) but normal iFGF23 (28.5 ± 1.1 pg/mL) levels at baseline. Within 24 hours of iron administration, cFGF23 levels fell by approximately 80% in both groups. In contrast, iFGF23 transiently increased in the FCM group alone, and was followed by a transient, asymptomatic reduction in serum phosphate <2.0 mg/dL in 10 women in the FCM group compared to none in the iron dextran group. Reduced serum phosphate was accompanied by increased urinary fractional excretion of phosphate, decreased calcitriol levels, and increased parathyroid hormone levels. These findings suggest that iron deficiency increases cFGF23 levels, and that certain iron preparations temporarily increase iFGF23 levels. We propose that intravenous iron lowers cFGF23 in humans by reducing fgf23 transcription as it does in mice, whereas carbohydrate moieties in certain iron preparations may simultaneously inhibit FGF23 degradation in osteocytes leading to transient increases in iFGF23 and reduced serum phosphate.read more
Citations
More filters
Journal ArticleDOI
Treatment options for anemia in the elderly.
TL;DR: A number of innovative anti-anemic drugs, like hepcidin modulators, Hypoxia Inducible Factor (HIF) stabilizers, and activin type II receptor agonists are entering the clinical arena and may substantially improve the therapeutic armamentarium to AE in the near future.
Journal ArticleDOI
p38MAPK controls fibroblast growth factor 23 (FGF23) synthesis in UMR106-osteoblast-like cells and in IDG-SW3 osteocytes.
TL;DR: p38MAPK induces FGF23 formation, an effect at least in part dependent on NFκB activity, as well as wogonin and withaferin A abrogated the stimulatory effect of anisomycin on Fgf23 gene expression.
Journal Article
Ferric carboxymaltose-induced hypophosphataemia after kidney transplantation.
TL;DR: Administration of a single dose of FCM may induce transient and mostly asymptomatic renal phosphate wasting and hypophosphataemia in kidney transplant recipients.
Journal ArticleDOI
Fibroblast-growth-factor-23 in heart failure with preserved ejection fraction: relation to exercise capacity and outcomes.
Prathap Kanagala,Prathap Kanagala,Jayanth R. Arnold,Jamal N Khan,Anvesha Singh,Gaurav S Gulsin,Mohamed Eltayeb,Pankaj Gupta,Iain B. Squire,Gerry P McCann,Leong L. Ng +10 more
TL;DR: This study aimed to assess plasma fibroblast growth factor 23 in patients with heart failure with preserved ejection fraction and its relation to inflammation, renal function, clinical and imaging characteristics, exercise capacity, and prognosis.
Journal ArticleDOI
The Role of Iron and Erythropoietin in the Association of Fibroblast Growth Factor 23 with Anemia in Chronic Kidney Disease in Humans.
Bernhard Bielesz,Thomas Reiter,Fabian Peter Hammerle,Wolfgang Winnicki,Marija Bojic,Andreas Gleiss,Heidi Kieweg,Franz Ratzinger,Gere Sunder-Plassmann,Rodrig Marculescu +9 more
TL;DR: In pre-dialysis CKD patients, the observed association of FGF23 with hemoglobin seems to be restricted to cFGF23 and largely explained by the iron status, and this association was largely accounted for by iron metabolism parameters.
References
More filters
Journal ArticleDOI
Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis.
Orlando M. Gutiérrez,Michael Mannstadt,Tamara Isakova,Jose Alejandro Rauh-Hain,Hector Tamez,Anand Shah,Kelsey Smith,Hang Lee,Ravi Thadhani,Harald Jüppner,Myles Wolf,Myles Wolf +11 more
TL;DR: Increased FGF-23 levels appear to be independently associated with mortality among patients who are beginning hemodialysis treatment, and a potential biomarker that can be used to guide strategies for the management of phosphorus balance in patients with chronic kidney disease is investigated.
Journal ArticleDOI
Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia
Takashi Shimada,Satoru Mizutani,Takanori Muto,Takashi Yoneya,Rieko Hino,Shu Takeda,Yasuhiro Takeuchi,Toshiro Fujita,Seiji Fukumoto,Takeyoshi Yamashita +9 more
TL;DR: It is concluded that overproduction of F GF23 causes TIO, whereas mutations in the FGF23 gene result in autosomal dominant hypophosphatemic rickets possibly by preventing proteolytic cleavage and enhancing biological activity of FGF 23.
Journal ArticleDOI
Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers.
TL;DR: Circulating FGF-23 was significantly elevated in patients with CKD and its concentration correlated with renal creatinine clearance, and in healthy volunteers, F GF-23 levels did not change after phosphate deprivation or phosphate loading.
Related Papers (5)
FGF23 induces left ventricular hypertrophy
Christian Faul,Ansel P. Amaral,Behzad N. Oskouei,Ming Chang Hu,Alexis Sloan,Tamara Isakova,Orlando M. Gutiérrez,Robier Aguillon-Prada,Joy Lincoln,Joshua M. Hare,Peter Mundel,Azorides R. Morales,Julia J. Scialla,Michael J. Fischer,Michael J. Fischer,Elsayed Z. Soliman,Jing Chen,Alan S. Go,Sylvia E. Rosas,Lisa Nessel,Raymond R. Townsend,Harold I. Feldman,Martin St. John Sutton,Akinlolu O. Ojo,Crystal A. Gadegbeku,Giovana Seno Di Marco,Stefan Reuter,Dominik Kentrup,Klaus Tiemann,Marcus Brand,Joseph A. Hill,Orson W. Moe,Makoto Kuro-o,John W. Kusek,Martin G. Keane,Myles Wolf +35 more